AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation - Lung Cancer
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
MET inhibitors in combination with other therapies in non-small cell lung cancer - Padda - Translational Lung Cancer Research
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
MET Inhibitors in NSCLC: Treatment Selection
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
MET inhibition in lung cancer - Menis - Translational Lung Cancer Research
Inhibition of c-Met in NSCLC. A, inhibition of c-Met protein expression... | Download Scientific Diagram
Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET Expression in Non-Small-Cell Lung Cancer: Testing, Treatment, and Future Directions This program is supported by an educational grant from. - ppt download
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations - Journal of Thoracic Oncology
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Active or Recent Clinical Trials of hepatocyte growth factor (HGF)-MET... | Download Table
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Met Inhibitors in Clinical Trials•
MET Expression in Non-Small-Cell Lung Cancer: Testing, Treatment, and Future Directions This program is supported by an educational grant from. - ppt download
c-Met inhibitor - Wikipedia
